HEALTHSTORY 858· JUNE 21, 2026

GLP-1 Weight Loss Drug Race Heats Up as Pfizer and Amgen Challenge Novo Nordisk and Eli Lilly

The scramble to compete in the GLP-1 weight loss drug market is intensifying. Pharmaceutical companies Pfizer and Amgen are developing products to take on Novo Nordisk's Wegovy and Eli Lilly's Zepbound

NDNewsDialy Desk2 MIN READPFE · LLY

SOURCE

statnews.com

← PREVIOUS STORY 857Fentanyl-Linked Chinese Network Ran Fake 'Zksync.jp' Token Scam, Nikkei Reports, With Losses Topping $1 Million NEXT STORY 859 →Pomerantz Files Class Action Against ServBanc Holdco, IF Bancorp Board Over IROQ Stock

Keep reading

More from the desk.

13HEALTH

FDA clears Ultragenyx gene therapy in a week of back-to-back regulatory action

A gene therapy has received clearance for use in American patients, one of at least two approvals the Food and Drug Administration processed in a short stretch this week. Gene therapy, in p

health1 MIN

18HEALTH

Health systems deploy AI chatbots to search and summarize patient records

Hospitals and health systems are deploying chatbots powered by large language models to search and summarize patient medical records, a technology shift driven by how bloated those records have become. A large language model is software…

health2 MIN

52HEALTH

Federal vaccine messaging is making new parents' decisions harder, says the AAP president

Fearmongering (spreading exaggerated alarm to shift behavior, rather than to inform a decision) is what some federal leaders are doing on childhood vaccines, the president of the American Academy of Pediatrics now argues. The AAP is the…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk